Jiang H, Bai X
J Multidiscip Healthc. 2025; 18:1147-1162.
PMID: 40026868
PMC: 11872101.
DOI: 10.2147/JMDH.S501551.
Li Z, Zhang W, Huang F, Hao S
Clinics (Sao Paulo). 2025; 80:100575.
PMID: 39869955
PMC: 11795829.
DOI: 10.1016/j.clinsp.2025.100575.
Renaghan A, Costa J, Esteves A
Kidney360. 2025; 6(2):317-330.
PMID: 39786913
PMC: 11882261.
DOI: 10.34067/KID.0000000692.
Malard F, Neri P, Bahlis N, Terpos E, Moukalled N, Hungria V
Nat Rev Dis Primers. 2024; 10(1):45.
PMID: 38937492
DOI: 10.1038/s41572-024-00529-7.
Shankar M, Anandh U, Guditi S
Indian J Nephrol. 2024; 34(1):31-36.
PMID: 38645901
PMC: 11003587.
DOI: 10.4103/ijn.ijn_362_22.
Descriptive analysis and prognostic factors in cats with myeloma-related disorders: A multicenter retrospective study of 50 cases.
Lecot L, Desmas-Bazelle I, Benjamin S, De Fornel P, Ponce F, Kornya M
J Vet Intern Med. 2024; 38(3):1693-1705.
PMID: 38517293
PMC: 11099758.
DOI: 10.1111/jvim.17051.
Incidence and reasons for discontinuation of first-line therapy in patients with multiple myeloma: results from a historical cohort, Brazil 2009-2020.
Teixeira M, Moreira Reis A, Drummond P, Malta J, Silveira L, Menezes de Padua C
Ann Hematol. 2024; 103(12):5881-5889.
PMID: 38459153
DOI: 10.1007/s00277-024-05684-1.
Oral health, dental treatment, and medication related osteonecrosis of the jaw in multiple myeloma - a longitudinal cohort study.
Olofsson R, Korytowska M, Almhojd U, Almstahl A, Cevik-Aras H
BMC Oral Health. 2024; 24(1):184.
PMID: 38317122
PMC: 10840162.
DOI: 10.1186/s12903-024-03943-1.
A Study on Renal Failure Management in Patients Diagnosed With Multiple Myeloma.
Almuhaysen L, Alaa A
Cureus. 2023; 15(10):e47460.
PMID: 38022312
PMC: 10660674.
DOI: 10.7759/cureus.47460.
Cytotoxic and Apoptotic Effects of Pinostilbene and Bortezomib Combination Treatment on Human Multiple Myeloma Cells.
Staskiewicz A, Wong E, Tucker M, Farhin R, Park J, Saade R
Int J Mol Sci. 2023; 24(16).
PMID: 37628771
PMC: 10454535.
DOI: 10.3390/ijms241612590.
Partnering With All Patients: Ensuring Shared Decision Making and Evidence-Based Management for Underrepresented Groups With Multiple Myeloma.
Cerchione C, Grant S, Ailawadhi S
Am Soc Clin Oncol Educ Book. 2023; 43:e390202.
PMID: 37167570
PMC: 10798363.
DOI: 10.1200/EDBK_390202.
The presence of two light chain bands on immunofixation is associated with poor outcomes in newly diagnosed multiple myeloma patients.
Jerbi A, Turki O, Hachicha H, Kallel Sarbeji F, Feki S, Mejdoub S
Ann Hematol. 2023; 102(6):1459-1466.
PMID: 37060464
DOI: 10.1007/s00277-023-05221-6.
Safety and efficacy of autologous stem cell transplantation in dialysis-dependent myeloma patients-The DIADEM study from the chronic malignancies working party of the EBMT.
Waszczuk-Gajda A, Gras L, de Wreede L, Sirait T, Illes A, Ozkurt Z
Bone Marrow Transplant. 2023; 58(4):424-429.
PMID: 36681775
DOI: 10.1038/s41409-023-01915-7.
High-cutoff hemodialysis in multiple myeloma patients with acute kidney injury.
Xing Y, Yan J, Yu Z, Zhao J, Wang Y, Li X
Front Oncol. 2022; 12:1024133.
PMID: 36387107
PMC: 9645355.
DOI: 10.3389/fonc.2022.1024133.
Serum Levels of Interleukin-1β and Disease Progression in Multiple Myeloma Patients: A Case and Control Study.
Teimuri Nobari S, Rasmi Y, Ansari M
Asian Pac J Cancer Prev. 2022; 23(9):2937-2942.
PMID: 36172655
DOI: 10.31557/APJCP.2022.23.9.2937.
Serum Free Light-Chain Ratio at Diagnosis Is Associated with Early Renal Damage in Multiple Myeloma: A Case Series Real-World Study.
De Novellis D, Fontana R, Carobene A, Serio B, Ferrara I, Martorelli M
Biomedicines. 2022; 10(7).
PMID: 35884962
PMC: 9313319.
DOI: 10.3390/biomedicines10071657.
Multiple myeloma: what a non-haematologist should know.
Nandra T, Devi A, Jones J
Clin Med (Lond). 2022; 22(3):230-233.
PMID: 35584836
PMC: 9135076.
DOI: 10.7861/clinmed.2022-0144.
Multiple Myeloma and Renal Failure: Mechanisms, Diagnosis, and Management.
Kundu S, Jha S, Rivera A, Flores Monar G, Islam H, Puttagunta S
Cureus. 2022; 14(2):e22585.
PMID: 35371791
PMC: 8958144.
DOI: 10.7759/cureus.22585.
Examining allostatic load, neighborhood socioeconomic status, symptom burden and mortality in multiple myeloma patients.
Obeng-Gyasi S, Graham N, Kumar S, Lee J, Jacobus S, Weiss M
Blood Cancer J. 2022; 12(4):53.
PMID: 35365604
PMC: 8975964.
DOI: 10.1038/s41408-022-00648-y.
Practical Considerations for the Daratumumab Management in Portuguese Routine Clinical Practice: Recommendations From an Expert Panel of Hematologists.
Geraldes C, Neves M, Chacim S, Leal da Costa F
Front Oncol. 2022; 11:817762.
PMID: 35186719
PMC: 8855501.
DOI: 10.3389/fonc.2021.817762.